Acupuncture and related techniques for type 2 diabetes mellitus

A systematic review protocol

Meilu Liu, MBa, Jianrong Chen, MD, Qing Ren, MM, Weifeng Zhu, PhD, Dongmei Yan, PhD, Heyun Nie, MM, Xiaofan Chen, MD, Xu Zhou, MD*

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a major global health problem. As a complementary treatment, acupuncture and related techniques are widely used to treat metabolic and endocrine diseases, but their efficacy and safety for T2DM are yet to be established. This systematic review will qualitatively and quantitatively summarize the current randomized controlled trial (RCT) evidence regarding the efficacy and safety of acupuncture and related techniques in patients with T2DM.

Methods: Comprehensive literature searches will be performed on PubMed, Embase, Cochrane Central Register of Controlled Trials, and a trial registry "ClinicalTrials.gov" from inception to December 3, 2018. We will include RCTs for patients with T2DM that compared acupuncture with placebo, antidiabetic drugs, lifestyle interventions, or the combination. Primary outcomes are fasting blood glucose and hemoglobin A1c. Secondary outcomes include 2-hour blood glucose, fasting insulin, homeostatic model assessment for insulin resistance, incidence of diabetic complications, and acupuncture-related adverse events. The risk of bias of the RCTs included in the review will be examined using a revised Cochrane handbook tool. Heterogeneity will be detected using Cochran Q test and I² statistics. With the use of random effects model, we will perform meta-analyses to pool results of RCTs. The effect measures will be weighted or standardized mean difference with 95% confidence intervals (CIs) for the continuous outcomes and risk ratio with 95% CIs for the dichotomous outcomes. Subgroup analyses and meta-regression with predefined effect modifiers will be performed to explore the sources of heterogeneity. Where appropriate, we will assess the possibility of reporting bias based on funnel plots and quantitative detection. We will provide an overall conclusion using the Grading of Recommendations Assessment, Development, and Evaluation system for each outcome.

Results: This study will provide accurate results and balanced inferences on the efficacy and safety of acupuncture and related techniques on T2DM.

Conclusion: This well-designed systematic review will establish high-quality evidence of the efficacy and safety of acupuncture and related techniques for T2DM to facilitate the clinical practice and guideline development.

PROSPERO registration number: CRD42018115639.

Abbreviations: EA = electroacupuncture, FBG = fasting blood glucose, FINS = fasting insulin, GRADE = Grading of Recommendations Assessment, Development, and Evaluation, 2hBG = 2-hour blood glucose, HbA1c = hemoglobin A1c, HOMA-IR = homeostatic model assessment for insulin resistance, MD = mean difference, MeSH = medical subject heading, PRISMA-P = Preferred Reporting Items for Systematic Reviews and Meta-Analysis - Protocol, RCT = randomized controlled trial, RR = risk ratio, SD = standard deviation, SMD = standardized mean difference, STRICTA = Standards for Reporting Interventions in Controlled Trials of Acupuncture, T2DM = type 2 diabetes mellitus, TCM = traditional Chinese medicine, WMD = weighted mean difference.

Keywords: acupuncture, protocol, systematic review, type 2 diabetes mellitus
1. Introduction

1.1. Description of the condition

Type 2 diabetes mellitus (T2DM), a metabolic disease manifested as a persistently high level of blood glucose, is caused by the progressive increase in insulin resistance and reduction in insulin secretion.[1] The International Diabetes Federation claimed that approximately 8.8% (415 million) adults suffered T2DM in 2015, and the proportion is predicted to rise to 10.4% (642 million) by 2040.[2] The vascular toxicity of long-term exposure to uncontrolled hyperglycemia increases the risk of a variety of diabetic complications.[3] Cardiovascular diseases are the primary macrovascular complications of T2DM and the leading cause of mortality. A registry study found that the risk of hospitalization owing to heart failure increased by 33% in patients with T2DM.[4] Diabetic patients are also prone to develop microvascular complications, of whom approximately 35% will finally develop diabetic nephropathy,[5] 12.3% diabetic retinopathy,[6] and 29.2% diabetic peripheral neuropathy.[7] Besides, the annual health expenditure by diabetic patients of different sexes and ages ranged from 612 to 1099 billion, which accounted for 11% to 20% of the total health expenditure.[8,9]

1.2. Description of the intervention

Acupuncture, a popular complementary therapy, was 1st recorded in a traditional Chinese medicine (TCM) classic, The Yellow Emperor’s Classic of Internal Medicine, 3000 years ago.[10] Based on TCM theory, acupuncture can be used to treat illnesses by stimulating specific acupoints.[11] Several studies have shown that acupuncture has effects on metabolic and endocrine diseases, such as polycystic ovarian syndrome, thyroid dysfunction, obesity, and T2DM with good safety.[12,13] Currently, available acupuncture and related techniques for these diseases include electroacupuncture (EA), acupressure, moxibustion, warm acupuncture, and transcutaneous acupoint electrical stimulation, and these techniques are commonly applied on the body and auricular acupoints.[14,15]

1.3. How the intervention might work

Many animal experiments have proved the hypoglycemic effect of acupuncture. A rat study revealed that acupuncture stimulations at Zhongwan (RN12) acupoint increased insulin secretion mediated by activation of opioid receptors.[16] Acupuncture also significantly reduced the insulin resistance in another rat study,[17] which may be associated with the inhibition of free fatty acid production through stimulating cholinergic nerves and activating nitric oxide synthase.[18] A human study also showed that acupuncture improved insulin sensitivity in patients with T2DM, as a result of the reduction in endogenous insulin concentration and the preservation of pancreatic β-cell function.[19] However, the hypoglycemic effects of acupuncture were not observed in rats with type 1 diabetes mellitus.[16,20]

1.4. Why it is important to perform this review

In the past decade, studies have shown that glycemic control in patients with T2DM has been unsatisfactory.[21,22] Drug dependence and resistance, caused by long-term use and lack of new or alternative treatments, are considered to be the main reasons for this clinical challenge.[23] Equally worrying is the adverse effects of hypoglycemic drugs. For example, alpha-glucosidase inhibitors have a high incidence of gastrointestinal side effects (e.g., abdominal distension and diarrhea) and thiazolidinediones may cause weight gain, limb fractures and even heart failure.[24,25] Acupuncture has potential benefits in efficacy and safety and is thus expected to be a promising complementary treatment for T2DM.[26] Previously, many randomized controlled trials (RCTs) investigated the effects of acupuncture on T2DM, but the results were inconsistent. Some RCTs found that fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) decreased significantly more after acupuncture compared to sham acupuncture,[27,28] but others had negative results.[29,30] Furthermore, multiple observational studies have yielded safety concerns about acupuncture in patients with T2DM. The adverse events included needling pain, hematoma, bleeding, infection, and more severe, necrotizing fasciitis.[31,32] Therefore, it is necessary to perform a systematic review to establish persuasive evidence of efficacy and safety of acupuncture on T2DM.

1.5. Objective

The aim of this systematic review is to determine the efficacy and safety of acupuncture and related techniques in patients with T2DM.

2. Methods

2.1. Study registration

This protocol has been registered in PROSPERO (no: CRD42018115639). The report was guided by the items of Preferred Reporting Items for Systematic Reviews and Meta-Analysis - Protocol (PRISMA-P).[33]

2.2. Criteria for including studies in this review

2.2.1. Types of studies. We will only include RCTs, the golden standard in therapeutic assessment. The authors should clearly claim that they performed random grouping. Both parallel and crossover trials are eligible, but only the data of the 1st phase will be used in the crossover trials.

2.2.2. Types of participants. Adult patients diagnosed with T2DM according to the American Diabetes Association standard[1] (FBG ≥ 126.1 mg/dL, HbA1c ≥ 6.5%, or random blood glucose ≥ 200.0 mg/dL) are eligible. Trials that recruited patients with type 1 diabetes mellitus, gestational diabetes mellitus, and secondary diabetes mellitus will be excluded. Trials that include patients complicated severe diseases (e.g., heart failure and stroke) are also ineligible.

2.2.3. Types of interventions

2.2.3.1. Experimental interventions. Acupuncture and related techniques on the body and auricular acupoints, including manual acupuncture, EA, acupressure, moxibustion, warm acupuncture, and transcutaneous acupoint electrical stimulation, are eligible. Highly heterogeneous interventions on acupoints or meridians will be excluded, such as laser acupuncture, acupoint catgut embedding, cupping, and Chinese Tuina. The eligible co-interventions include antidiabetic drugs, lifestyle interventions (exercise, diets), whereas Chinese herbs are not allowed.

2.2.3.2. Comparator interventions. The eligible comparators include placebo (i.e., sham acupuncture), antidiabetic drugs, lifestyle interventions, and the combination. Ineligible compar-
**2.4. Selection of studies.**

**2.4.1. Selection of studies.**

Two reviewers, working in pairs, will 1st read the titles and abstracts yielded by the search into Endnote X9 (Clarivate Analytics US LLC, Philadelphia) for management and deduplication. Two reviewers will independently extract the data from the eligible RCTs, and any discrepancy will be settled through discussions or consultations with a senior reviewer. We will give a flowchart to present the detailed screening process compliant with PRISMA-P (Fig. 1).

**2.4.2. Data extraction and management.** Two reviewers will independently extract the data from the eligible RCTs, and any discrepancy will be settled through discussions or consultations with a senior reviewer. We will extract the following information:

1. Study characteristics: 1st author, publication year, country, language, eligibility criteria, type of acupuncture, details of acupuncture methods (according to the Standards for Reporting Interventions in Controlled Trials of Acupuncture [STRICTA] criteria\(^{35}\)), type of control, number of patients, follow-up time, and dropout rate.

2. Patient characteristics: gender, age, comorbidities, use of antidiabetic drugs, and baseline FBG, HbA1c, and body mass index.

3. Outcome data: mean and standard deviation (SD)/standard error will be extracted for continuous outcomes; the number of events and total population will be extracted for dichotomous outcomes. If a study provides data of multiple follow-up nodes, we will only use the data of the final time point data for data analysis.

**2.4.3. Assessment of risk of bias.** We will use the Gordon H. Guyatt’s revision of Cochrane risk of bias tool for the assessment.\(^{36,37}\) Seven aspects of risk of bias will be assessed, including random sequence generation, allocation concealment, blinding of patients and caregivers, blinding of outcome assessment, data completeness, selective outcome reporting, and other bias (e.g., extremely imbalanced baselines between the groups). In contrast to the original tool, this revision requires the determination of standard deviations for dichotomous outcomes

### Table 1

| No. | Search terms                                      | No. | Search terms                                      |
|-----|---------------------------------------------------|-----|---------------------------------------------------|
| 1   | diabetes mellitus[mh]                             | 20  | silver needle\(^{\text{tw}}\)                     |
| 2   | diabetes\(^{\text{tw}}\)                         | 21  | edged needle\(^{\text{tw}}\)                     |
| 3   | T2DM\(^{\text{tw}}\)                             | 22  | intradermal needle\(^{\text{tw}}\)                |
| 4   | OR 1–3                                           | 23  | plum-blossom needle\(^{\text{tw}}\)              |
| 5   | acupuncture[mh]                                  | 24  | microwave needle\(^{\text{tw}}\)                 |
| 6   | acupuncture therapy[mh]                          | 25  | superficial needle\(^{\text{tw}}\)               |
| 7   | auriculotherapy[mh]                              | 26  | needle\(^{\text{tw}}\)                          |
| 8   | moxibustion[mh]                                  | 27  | acupuncture\(^{\text{tw}}\)                      |
| 9   | acupressure[mh]                                  | 28  | point applic\(^{\text{tw}}\)                    |
| 10  | acupuncture\(^{\text{tw}}\)                      | 29  | meridian\(^{\text{tw}}\)                        |
| 11  | moxibustion\(^{\text{tw}}\)                      | 30  | acupressure\(^{\text{tw}}\)                     |
| 12  | auriculotherapy\(^{\text{tw}}\)                  | 31  | auricular point\(^{\text{tw}}\)                  |
| 13  | electro-acupuncture\(^{\text{tw}}\)              | 32  | percutaneous electrical stimulation\(^{\text{tw}}\) |
| 14  | electroacupuncture\(^{\text{tw}}\)              | 33  | OR 5-32                                         |
| 15  | transcutaneous acu\(_{n}^{\text{p}}\)electrical stimulation | 34  | 4 AND 33                                        |
| 16  | needle knife\(^{\text{tw}}\)                     | 35  | animal[mh]                                       |
| 17  | skin needl\(^{\text{tw}}\)                       | 36  | humans[mh]                                       |
| 18  | filiform needl\(^{\text{tw}}\)                   | 37  | 35 NOT 96                                        |
| 19  | fine needl\(^{\text{tw}}\)                       | 38  | 34 AND 37                                        |

\(^{\text{tw}}\)T2DM = type 2 diabetes mellitus.
We will finally classify the overall risk of bias into three levels: low (all items have a low or probably low risk of bias), moderate (at least 1 item probably has a high risk of bias), and high (at least 1 item definitely has a high risk of bias). The assessment will be carried out by 2 reviewers, and any discrepancy will be resolved through consultation with a senior reviewer.

2.4.4. Measures of treatment effect. We will use mean difference (MD) with 95% confidence intervals (CIs) as the effect measure for continuous outcomes. For dichotomous data, we will use risk ratio (RR) with 95% CIs as the effect measure.

2.4.5. Dealing with missing data. For continuous variables, we will estimate the missing mean and SD of change from baseline using the data at baseline and the last follow-up by the Cochrane Collaboration method.[38] Data described as median and range or interquartile range will be converted to mean and SD by the Wan method.[38] We will also try to contact authors to request for the missing data that cannot be imputed or inferred from the article.

2.4.6. Assessment of heterogeneity. We will conduct the Cochran Q test and estimate the $I^2$ statistics to detect the heterogeneity for each outcome.[36] A $P$-value $<.1$ or $I^2 > 50\%$ indicates significant heterogeneity; otherwise, heterogeneity is acceptable.

2.4.7. Assessment of reporting biases. For the outcomes in which at least 10 RCTs are included, we will assess the possibility of reporting bias. The funnel plots will be used to assess asymmetry visually. The Egger test[39] (for continuous data) and the Harbord test[40] (for dichotomous data) will be used for the quantitative assessment. A $P < .05$ indicates a significant publication bias.

2.4.8. Data synthesis. In the meta-analysis of continuous outcomes, we will pool the weighted MD (WMD), or

---

**Figure 1. Flow diagram of study selection.**

Records searched from database:
- PubMed (n = )
- EMBASE (n = )
- Cochrane library (n = )
- Clinical Trials.gov (n = )

Records from other sources:
- Records obtained from references of relevant reviews (n = )

Records after duplicates removed (n = )

Records screened (n = )

Records excluded (n = )

Reasons for exclusion in full-text screening (n = )
- Not randomized controlled trial (n = )
- Ineligible patients (n = )
- Ineligible interventions (n = )
- Ineligible controls (n = )
- No outcomes of interest (n = )

Full-text articles assessed for eligibility (n = )

Studies included in systematic review (n = )
standardized MD (SMD) if the units cannot be unified, by the inverse variance method. An SMD < 0.5 will be generally considered to be a small effect size, 0.5 to 0.8 to be moderate, and >0.8 to be large.\textsuperscript{[41]} In the meta-analysis of dichotomous outcomes, we will pool RR by the Mantel–Haenszel method. When necessary, the logRR/WMD/SMD and standard error will be calculated and pooled by the inverse variance method. Random effects model will always be used to combine the data independent of the magnitude of heterogeneity. We will conduct a narrative summary when the results are inappropriate to be pooled due to the substantial clinical or methodologic heterogeneity. We will use forest plots to present the results of the meta-analyses. The statistical analysis will be performed using RevMan v5.3.5 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) and Stata v14.0 (StataCorp Lp, TX).

2.4.9. Subgroup analysis and investigation of heterogeneity.

If data are available, we will perform subgroup analyses and meta-regression to explore the sources of heterogeneity. Four independent variables are predefined: type of acupuncture (skin-pierced acupuncture vs others); type of control group (antidiabetic drugs vs nondrug controls); risk of bias (high vs moderate vs low); follow-up period (≥8 vs <8 weeks). We will also consider performing post-hoc subgroup analyses and meta-regression for other independent variables if necessary.

2.4.10. Sensitivity analysis.

To evaluate the robustness of the pooled results, we will perform sensitive analysis by including only RCTs with a low or moderate risk of bias and using an alternative effect model (random effects model vs fixed-effect model).

2.4.11. Summary of evidence.

We will rate the quality of evidence for each outcome using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) instrument.\textsuperscript{[42]} The quality of evidence will initially be high in all outcomes but will be degraded to be moderate, low, or very low, if there are weaknesses in risk of bias, heterogeneity, indirectness, imprecision, and publication bias. Two reviewers will independently perform this process, and a 3rd reviewer will join if necessary.

2.5. Ethics and dissemination

Ethics approval is not required in this study because no individual data from participants will be involved. We aim to publish this systematic review on a peer-reviewed journal.

3. Discussion

A few systematic reviews discussed the topic of acupuncture for T2DM previously.\textsuperscript{[43–45]} However, the targets of these reviews are substantially different from ours, one of which only included herbal acupuncture,\textsuperscript{[43]} one only included manual acupuncture,\textsuperscript{[44]} and the other one only focused on diabetic gastroparesis.\textsuperscript{[45]} Except for the 1st one, all reviews did not assess the outcomes related to the hypoglycemic effects (e.g., FBG, HbA1c, and FINS). These reviews also have substantial methodologic limitations, such as lack of detailed descriptions on the acupuncture methods according to STRICTA criteria,\textsuperscript{[43–45]} high heterogeneity without explanation,\textsuperscript{[43–45]} and no assessment of the quality of evidence.\textsuperscript{[43,44]}

In contrast to the published systematical reviews, our review will include all acupuncture and related techniques and focus on outcomes reflecting the hypoglycemic effects and the safety. There will be several methodologic advantages in our study. First, we will judge “probably yes” and “probably no” for the items with “unclear” risk of bias to achieve a more transparent assessment. Second, we will test 4 predefined hypotheses in the subgroup analysis and meta-regression based on the consideration of clinical and biologic mechanisms, which will enhance the credibility of the results.\textsuperscript{[46]} Third, we will use the GRADE instrument to critically assess the quality of evidence of each outcome to make objective conclusions.

A potential limitation in our review is that we will include RCTs with various characteristics (e.g., different types of acupuncture and control, inconsistent length of follow-up), which may inevitably lead to heterogeneity. Although we plan to perform relevant subgroup analysis and meta-regression, the source of heterogeneity may be hard to be fully elucidated due to insufficient data. Besides, we intend to only search 4 central English databases, which means that the RCTs only recorded in the Chinese databases will be omitted and seems to cause selection bias. Nevertheless, some methodologists have deemed those Chinese RCTs extremely unreliable, as most of them only describe “random grouping” without further information about randomization and lack of trial registration and monitoring.\textsuperscript{[47,48]} Therefore, the exclusion would be helpful to reduce the overall risk of bias rather than leading to disadvantages. We believe that this well-designed systematic review will establish high-quality evidence to facilitate clinical practice and guideline development of acupuncture for T2DM.

Author contributions

Conceptualization: Xu Zhou
Funding acquisition: Xu Zhou
Investigation: Weifeng Zhu, Dongmei Yan, Heyun Nie, Xiaofan Chen
Methodology: Meilu Liu, Jianrong Chen
Writing – original draft: Meilu Liu, Jianrong Chen
Writing – review & editing: Qing Ren, Xu Zhou
Xu Zhou orcid: 0000-0002-9541-4796

References

[1] American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes - 2018. Diabetes Care 2017;41 (Suppl 1):S13–27.
[2] Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017;128:40–50.
[3] Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2011;91:137–88.
[4] Cavender MA, Steg PG, Smith SC, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death. Circulation 2015;132:2923–31.
[5] Tesch GH. Diabetic nephropathy is this an immune disorder? Clin Sci (Lond) 2017;131:2183–99.
[6] Rodriguez-Poncelas A, Miravet-Jimenez S, Casellas A, et al. Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain). Br J Ophthalmol 2015;99:1628–33.
[7] Bansal D, Gudala K, Muthyala H, et al. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. J Diabetes Investig 2014;5:714–21.
[8] da Rocha Fernandes J, Ogurtsova K, Linnenkamp U, et al. IDF diabetes atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract 2016;117:48–54.
[9] World Health Organization national health account database 2014. Available at: http://apps.who.int/nhad/database. Accessed November 10, 2018.

[10] White A, Ernst E. A brief history of acupuncture. Rheumatology (Oxford) 2004;43:662–3.

[11] Acar HV. Acupuncture and related techniques during perioperative period: a literature review. Complement Ther Med 2016;29:48–55.

[12] Liang F, Koya D. Acupuncture: is it effective for treatment of insulin resistance? Diabetes Obes Metab 2010;12:553–69.

[13] Zollman C, Vickers A. ABC of complementary medicine. Users and practitioners of complementary medicine. BMJ 1999;319:836–8.

[14] Feng Y, Fang Y, Wang Y, et al. Acupoint therapy on diabetes mellitus and its common chronic complications: a review of its mechanisms. Biomed Res Int 2018;2018:3128378.

[15] Cheng FK. An overview of the contribution of acupuncture to thyroid disorders. J Integr Med 2018;16:375–83.

[16] Chang SL, Lin JG, Chi TC, et al. An insulin-dependent hypoglycaemia induced by electroacupuncture at the Zhongwan (CV12) acupoint in diabetic rats. Diabetologia 1999;42:250–5.

[17] Ishizaki N, Okushi N, Yano T, et al. Improvement in glucose tolerance as a result of enhanced insulin sensitivity during electroacupuncture in spontaneously diabetic Goto-Kakizaki rats. Metabolism 2009;58:1372–8.

[18] Lin RT, Chen CY, Tseng CY, et al. Electroacupuncture improves glucose tolerance through cholinergic nerve and nitric oxide synthase effects in rats. Neurosci Lett 2011;494:114–8.

[19] Lin RT, Pai HC, Lee YC, et al. Electroacupuncture and rosiglitazone combined therapy as a means of treating insulin resistance and type 2 diabetes mellitus: a randomized controlled trial. Evid Based Complement Alternat Med 2013;2013:969824.

[20] Lin RT, Tseng CY, Lee YC, et al. Acupoint-specific, frequency-dependent, and improved insulin sensitivity hypoglycemic effect of electroacupuncture applied to drug-combined therapy studied by a randomized control clinical trial. Evid Based Complement Alternat Med 2014;2014:7317457.

[21] Stone MA, Charpentier G, Doggen K, et al. Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care 2013;36:2628–38.

[22] Carls G, Huynh J, Tuttle E, et al. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Therapy 2017;8:863–73.

[23] Wei JP, Wang QH, Zheng HJ, et al. Rosiglitazone evaluated for diabetes mellitus: a randomized controlled trial. Evid Based Complement Alternat Med 2013;2013:969824.

[24] Goodarzi MO, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab 2005;7:654–65.

[25] Taylor P, Pezzullo L, Grant SJ, et al. Cost-effectiveness of acupuncture for chronic nonspecific low back pain. Pain Pract 2014;14:599–606.

[26] Kumar R, Mooventhiran A, Manjunath NK. Immediate effect of needleing at CV-12 (Zhongwan) acupuncture point on blood glucose level in patients with type 2 diabetes mellitus: a pilot randomized placebo-controlled trial. J Acupunct Meridian Stud 2017;10:240–4.

[27] Liu et al. Medicine (2019) 98:2

[28] Wang S, Chen Z, Fu P, et al. Use of auricular acupuncture to improve the quality of life in diabetic patients with chronic kidney diseases: a prospective randomized controlled trial. Evid Based Complement Alternat Med 2014;2014:343608.

[29] Jiang H, Shi K, Li X, et al. Clinical study on the wrist-ankle acupuncture treatment for 30 cases of diabetic peripheral neuritis. J Tradit Chin Med 2006;26:8–12.

[30] Li G, Huang C, Zhang X, et al. The short-term effects of acupuncture on patients with diabetic gastroparesis: a randomised crossover study. Acupunct Med 2015;33:204–9.

[31] Melchart D, Weidenhammer W, Steng A, et al. Prospective investigation of adverse effects of acupuncture in 97 733 patients. Arch Intern Med 2004;164:104–5.

[32] Sun X, Ioannidis JP, Agoritsas T, et al. How to use a subgroup analysis: extending the CONSORT statement. J Altern Complement Med 2013;19:638–42.

[33] Faraone SV. Interpreting estimates of treatment effects: implications for managed care. P T 2008;33:700–11.

[34] Higgins JPT, Churchill R, Chandler J, Cumpston MS. Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017): The Cochrane Collaboration 2011. Available at: http://www.training.cochrane.org/handbook. Accessed November 17, 2018.

[35] Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006;25:3443–57.

[36] Faraone SV. Interpreting estimates of treatment effects: implications for managed care. P T 2008;33:700–11.

[37] Rosiglitazone: a review of its mechanisms of action. Exp Ther Med 2012;3:3249–56.

[38] Sun X, Ioannidis JP, Agoritsas T, et al. How to use a subgroup analysis: extending the CONSORT statement. J Altern Complement Med 2013;19:638–42.

[39] Carls G, Huynh J, Tuttle E, et al. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Therapy 2017;8:863–73.

[40] Wei JP, Wang QH, Zheng HJ, et al. Rosiglitazone evaluated for diabetes mellitus: a randomized controlled trial. Evid Based Complement Alternat Med 2013;2013:969824.

[41] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[42] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[43] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[44] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[45] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[46] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[47] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[48] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[49] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[50] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[51] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[52] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[53] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[54] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.

[55] Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009;10:46.